Antidiuretic Hormone - Podcast Version TeachMePhysiology 0:00 / 0:00 1x 0.25x 0.5x 0.75x 1x 1.25x 1.5x 1.75x 2x Antidiuretic hormone (ADH), also known as vasopressin, is a small peptide hormone which regulates water retention and plasma osmolality. It is one of only two hormones secreted by the posterior pituitary gland. In this article, we will discuss the synthesis, storage, release and action of ADH, and consider its clinical relevance. Pro Feature - 3D Model You've Discovered a Pro Feature Access our 3D Model Library Explore, cut, dissect, annotate and manipulate our 3D models to visualise anatomy in a dynamic, interactive way. Learn More Synthesis and Storage ADH is synthesised in the supraoptic and paraventricular nuclei in the hypothalamus. It is then transported via the nerve axon to the posterior pituitary gland (or neurohypophysis), forming the hypothalamic-hypophyseal tract. ADH is then stored in the posterior pituitary gland until it is ready to be secreted into the circulation. Release of ADH The release of ADH is controlled by several factors, the two most influential being changes in plasma osmolality, and volume status. Other factors such as exercise, angiotensin II, and emotional states such as pain also promote ADH release. ADH secretion is inhibited by atrial natriuretic peptide (ANP), which is released during atrial stretch in response to increased blood pressure, as well as alcohol and certain medications. Plasma osmolality Osmoreceptors are located in hypothalamus, specifically in the organum vasculosum of the lamina terminalis (OVLT) and the subfornical organ. Both are sensory circumventricular organs as they lack a blood-brain barrier. This allows them to directly detect changes in systemic plasma osmolality (which is directly proportional to osmotic pressure). When osmolality increases, water exits osmoreceptors by osmosis down its concentration gradient into the plasma. As water leaves, osmoreceptor cell shrinkage triggers afferent signals from the hypothalamus to the posterior pituitary gland, causing ADH release. Thus, hypothalamic osmoreceptors respond to changes in plasma osmolality by adjusting ADH secretion. Plasma osmolality is also affected by the total body plasma volume – a fall in plasma volume causes an increase in the plasma sodium (Na+) concentration, increasing osmolality. Thus, osmoreceptors also respond to changes in volume status. When total body volume increases, reducing plasma osmolality, water moves down its concentration gradient from the plasma, into osmoreceptors. The subsequent expansion of osmoreceptor cells triggers afferent signals to be sent from the hypothalamus to the posterior pituitary gland, decreasing ADH release. Volume Status Baroreceptors also respond to changes in volume status to affect ADH release. They are located in the left atrium, carotid artery and aortic arch and detect changes in arterial blood pressure. Arterial blood pressure is affected by circulating blood volume. A reduction in blood pressure is relayed via baroreceptors to the vagus nerve, which sends afferent signals that directly stimulate ADH release from the posterior pituitary. Conversely, in a hypervolemic state, blood pressure increases and ADH secretion is reduced. Action of ADH The main action of ADH in the kidney is to regulate the volume and osmolality of urine. It acts in the distal convoluted tubule (DCT) and collecting duct (CD) to achieve this. When plasma osmolality and ADH secretion increases, ADH binds to vasopressin 2 (V2 receptors, a G-protein coupled receptor) on principal cells in the DCT and CD. This promotes the transcription and insertion of aquaporin–2 channels into the apical membrane of these cells. Consequently, the permeability of the DCT and CD cells to water increases. This allows water to move down its concentration gradient from the lumen of the nephron back into the bloodstream. This reabsorption of water increases total blood volume, thereby reducing and normalising plasma osmolality whilst concentrating the urine. OpenStax College (CC BY 3.0 [https://creativecommons.org/licenses/by/3.0/deed.en]), via Wikimedia Commons Figure 1Mechanism of water reabsorption in the kidney When plasma osmolality decreases and ADH release is reduced, fewer aquaporin-2 channels are inserted into the apical membrane of the DCT and CD cells. The subsequent reduction in water reabsorption, reduces blood volume and increases and normalising plasma osmolality whilst producing a dilute urine. In high concentrations, ADH also binds V1 receptors on vascular smooth muscle cells. This causes vasoconstriction, increasing peripheral vascular resistance and therefore blood pressure. This is useful in restoring blood pressure during hypovolemic shock. Created in BioRender Figure 2Regulation of the ADH axis Clinical Relevance Diabetes Insipidus This condition is characterised by excessive thirst and production of large volumes of dilute urine. It is usually diagnosed by the presence of high plasma osmolality and low urine osmolality. A water deprivation test can help with diagnosis. There are two different types of diabetes insipidus: Cranial diabetes insipidus – due to a lack of ADH secretion from the posterior pituitary gland. This may be idiopathic or secondary to damage by tumours, infection or trauma. It is typically treated with desmopressin, a synthetic ADH analogue. Nephrogenic diabetes insipidus – due to a failure of the kidneys to respond to ADH and reabsorb water from the filtrate. ADH release from the pituitary gland is sufficient. Causes include genetic predisposition, electrolyte disturbances and some medications (e.g. lithium). Management is difficult but high-dose ADH analogues, thiazide diuretics, amiloride and NSAIDs can be trialled. Clinical Relevance Syndrome of Inappropriate ADH (SIADH) secretion SIADH is characterised by hyponatraemia secondary to excessive reabsorption of free water. Symptoms can be mild, but in severe cases, cerebral oedema and resultant neurological dysfunction can occur. Common causes of SIADH include: Malignancy e.g. small cell lung cancer Brain injury e.g. stroke or subarachnoid haemorrhage Infections e.g. atypical pneumonia, meningitis Drugs e.g. carbamazepine, sulfonylureas When treating SIADH care must be taken to correct Na+ slowly or severe neurological sequelae (osmotic demyelination syndrome or cerebral pontine myelinolysis) may occur. Management hinges on fluid restriction but demeclocycline may be used in some cases. Do you think you’re ready? Take the quiz below Pro Feature - Quiz Antidiuretic Hormone Question 1 of 3 Submitting... Skip Next Rate question: You scored 0% Skipped: 0/3 More Questions Available Upgrade to TeachMePhysiology Pro Challenge yourself with over 2100 multiple-choice questions to reinforce learning Learn More Rate This Article